Tempest Therapeutics (TPST) Other Non-Current Assets (2012 - 2026)
Tempest Therapeutics (TPST) posted Other Non-Current Assets of $517000.0 for Q4 2025, little changed sequentially from $519000.0 in Q3 2025, and up 6.6% YoY from $485000.0 in Q4 2024.
Tempest Therapeutics (TPST) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Tempest Therapeutics has reported Other Non-Current Assets for 14 years, with the latest figure at $517000.0 in Q4 2025.
- Quarterly Other Non-Current Assets rose 6.6% year-over-year to $517000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $517000.0 (up 6.6% YoY) and the FY2025 annual result came in at $517000.0, up 6.6% from the prior year.
- Other Non-Current Assets steadied at $517000.0 in Q4 2025 per TPST's latest filing, from $519000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $683000.0 in Q3 2022 and troughed at $111000.0 in Q1 2021.
- A 5-year average of $405900.0 and a median of $448000.0 in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2021 and 2022: Other Non-Current Assets sank 80.0% in 2021, then soared 509.82% in 2022.
- Over 5 years, Other Non-Current Assets stood at $111000.0 in 2021, then soared by 286.49% to $429000.0 in 2022, then increased by 4.43% to $448000.0 in 2023, then grew by 8.26% to $485000.0 in 2024, then gained by 6.6% to $517000.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $517000.0, $519000.0, and $529000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 62.96 Mn |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - | 501,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 501,000.00 |
| Dec 31, 2025 | 517,000.00 |
| Sep 30, 2025 | 519,000.00 |
| Jun 30, 2025 | 529,000.00 |
| Mar 31, 2025 | 538,000.00 |
| Dec 31, 2024 | 485,000.00 |
| Sep 30, 2024 | 448,000.00 |
| Jun 30, 2024 | 448,000.00 |
| Mar 31, 2024 | 448,000.00 |
| Dec 31, 2023 | 448,000.00 |
| Sep 30, 2023 | 393,000.00 |
| Jun 30, 2023 | 398,000.00 |
| Mar 31, 2023 | 429,000.00 |
| Dec 31, 2022 | 429,000.00 |
| Sep 30, 2022 | 683,000.00 |
| Jun 30, 2022 | 480,000.00 |
| Mar 31, 2022 | 480,000.00 |
| Dec 31, 2021 | 111,000.00 |
| Sep 30, 2021 | 112,000.00 |
| Jun 30, 2021 | 112,000.00 |